COPD and cognitive impairment: the role of hypoxemia and oxygen therapy

Neeta Thakur¹
Paul D Blanc²
Laura J Julian¹
Edward H Yelin³
Patricia P Katz³
Stephen Sidney⁴
Carlos Iribarren⁴
Mark D Eisner¹,²

¹Department of Medicine, ²Division of Occupational and Environmental Medicine and Division of Pulmonary and Critical Care Medicine, ³Institute for Health Policy Studies, Department of Medicine, University of California, San Francisco, CA, USA, ⁴Division of Research, Kaiser Permanente, Oakland, CA, USA

Background: Several studies have shown an association between chronic obstructive pulmonary disease (COPD) and cognitive impairment. These studies have been limited by methodological issues such as diagnostic uncertainty, cross-sectional design, small sample size, or lack of appropriate referent group. This study aimed to elucidate the association between COPD and the risk of cognitive impairment compared to referent subjects without COPD. In patients with established COPD, we evaluated the impact of disease severity and impairment of respiratory physiology on cognitive impairment and the potential mitigating role of oxygen therapy.

Methods: We used the Function, Living, Outcomes and Work (FLOW) cohort study of adults with COPD (n = 1202) and referent subjects matched by age, sex, and race (n = 302) to study the potential risk factors for cognitive impairment among subjects with COPD. Cognitive impairment was defined as a Mini-Mental State Exam score of ≤ 24 points. Disease severity was using Forced Expiratory Volume in one second (FEV₁); the validated COPD Severity Score; and the BMI (Body Mass Index), Obstruction, Dyspnea, Exercise Capacity (BODE) Index. Multivariable analysis was used to control for confounding by age, sex, race, educational attainment, and cigarette smoking.

Results: COPD was associated with a substantive risk of cognitive impairment compared to referent subjects (odds ratio [OR] 2.42; 95% confidence interval [CI] 1.043–6.64). Among COPD patients, none of the COPD severity measures were associated with the risk of cognitive impairment (P ≥ 0.20 in all cases). Low baseline oxygen saturation was related to increased risk of cognitive impairment (OR for oxygen saturation ≤ 88% (OR 5.45; 95% CI 1.014–29.2; P = 0.048). Conversely, regular use of supplemental oxygen therapy decreased the risk for cognitive impairment (OR 0.14; 95% CI 0.07–0.27; P < 0.0001).

Conclusion: COPD is a major risk factor for cognitive impairment. Among patients with COPD, hypoxemia is a major contributor and regular use of home oxygen is protective. Health care providers should consider screening their COPD patients for cognitive impairment.

Keywords: chronic obstructive pulmonary disease

Introduction

Chronic obstructive pulmonary disease (COPD) is characterized by the irreversible loss of lung function. Although COPD has been traditionally considered as a disease primarily affecting the lungs, its systemic effects have been increasingly recognized with diverse manifestations involving body systems distant from the lung.¹,² The brain, in particular, may be vulnerable to the systemic effects of COPD.³–⁸ Several features of the disease may contribute to impaired cognitive function, including hypoxemia and comorbid cardiovascular disease.⁴–⁶ In addition, COPD may lead patients to curtail their physical activity which may, in turn, further increase the risk of cognitive impairment.¹⁰
Although there is a plausible link between COPD and cognitive impairment, the existing literature is limited by methodological issues such as diagnostic uncertainty, cross-sectional design, small sample size, or lack of appropriate referent group. In a large cohort study of COPD, we aimed to elucidate the impact of COPD on the risk of cognitive impairment compared to a matched referent group without disease. Among patients with established COPD, we evaluated the impact of disease severity and impairment of respiratory physiology on cognitive impairment and the potential mitigating role of oxygen therapy.

Methods

Recruitment of the cohort and referent subjects

The current study is a matched case-referent analysis conducted within the Function, Living, Outcomes, and Work (FLOW) study of COPD. The FLOW study is an ongoing prospective cohort study of adult members of an integrated health care delivery system with a physician’s diagnosis of COPD with an accompanying matched control group. Recruitment methods have been previously reported in detail. We recruited a cohort of 1,202 Kaiser Permanente Medical Care Program (KPMCP) members who were recently treated for COPD using a validated algorithm based both on health care utilization and pharmacy dispensing for COPD. A control group of 302 subjects without COPD were recruited who were matched by age, sex, and race to the cohort members. Spirometry confirmed that none of the controls met Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria for COPD. At baseline assessment, we conducted structured telephone interviews that ascertained sociodemographic characteristics, COPD clinical history, and health status. Research clinic visits included spirometry, other physical assessments, and cognitive testing. The study was approved both by the University of California, San Francisco Committee on Human Research and the Kaiser Foundation Research Institute’s institutional review board and all participants provided written informed consent.

Structured telephone interviews

All subjects (COPD subjects and non-COPD referents) underwent 30–40 minute structured telephone interviews that ascertained sociodemographic characteristics, cigarette smoking, health status, and home oxygen use. As in our previous studies, we defined educational attainment as high school or less, some college, or college/graduate degree. Race-ethnicity was categorized as white non-Hispanic, African American, Asian/Pacific Islander, Hispanic, or other. Cigarette smoking was measured using questions developed for the National Health Interview Survey (NHIS) and was defined as current smoking, past smoking, or never smoked. We assessed comorbid cardiovascular conditions using survey items modified from the NHIS. These include a reported physician’s diagnosis of coronary artery disease, congestive heart failure, or stroke based on our previous work.

Assessment of pulmonary physiology

Baseline oxygen saturation was measured at rest in the seated position using the Nellcor N-180 (Covidien-Nellcor, Boulder, CO). Most subjects were measured on room air; 61 subjects had oxygen saturation measured on their prescribed supplemental oxygen (range 1–4 liters/minute).

To measure pulmonary function, we conducted spirometry according to American Thoracic Society (ATS) Guidelines. We used the EasyOne™ Frontline spirometer (ndd Medical Technologies, Chelmsford, MA, USA), which is known for its reliability, accuracy, and durability and has been widely used in epidemiologic research. Because research clinic examinations were conducted by trained nonmedical personnel, we did not administer bronchodilators for study purposes. However, 90% of subjects had taken their own short-acting bronchodilator within 4 hours of spirometry or had taken a long-acting bronchodilator earlier in the same day.

Measurement of COPD severity

We used a combined approach to measure COPD severity. We used a disease-specific COPD severity score that we had previously developed and validated for use in epidemiologic and outcomes research. Based on survey responses, the COPD severity score is comprised of five overall aspects of COPD severity: respiratory symptoms, systemic corticosteroid use, other COPD medication use, previous hospitalization or intubation for respiratory disease, and home oxygen use. Each item was weighted based on clinical aspects of the disease and its expected contribution to overall COPD severity. Possible total scores range from 0 to 35, with higher scores reflecting more severe COPD.

We also used the validated BMI (Body Mass Index), Obstruction, Dyspnea, Exercise Capacity (BODE) Index, which is a multi-modal measure of disease severity. The BODE Index is based on the body-mass index ($B$), the degree of airflow obstruction ($O$) measured by Forced Expiratory Volume in one second (FEV$_1$), grade of dyspnea ($D$) assessed by the modified Medical Research Council (MRC)
Dyspnea Scale, and exercise capacity ($E$) measured by the six-minute-walk test. Each component is assigned a specific score and the total score ranges from 0 to 10 points (higher scores indicate greater severity). The BODE index predicts death and other poor outcomes in COPD.28–30

Cognitive assessment
At the time of the research clinic visit, cognitive function was measured using the Mini-Mental State Examination, which is the most commonly used screening test for cognitive impairment in North America.31 The 11-item instrument assesses orientation, recall ability, short-term memory, and arithmetic ability.32 It evaluates most of the main domains of cognitive status and has been extensively validated.31–36 We used the recommended cut-point score of <24 points out of the total possible 30 points to indicate cognitive impairment.37

Statistical analysis
Statistical analysis was conducted using SAS software, version 9.1 (SAS Institute, Inc, Cary, NC, USA) and Stata 10 (College Park, TX, USA). Bivariate comparisons were carried out using $t$-test for continuous variables and the chi-square test for categorical variables. We used logistic regression analysis to examine the association between COPD (vs referent) and the risk of cognitive impairment, controlling for age, sex, race, educational attainment, and smoking history (past smoking and current smoking as indicator variables).

In the COPD cohort, we used multivariable logistic regression analysis to elucidate the association between COPD severity measures and the risk of cognitive impairment. Risk estimates (ie, odds ratios) were expressed per a 0.5 standard deviation of each predictor variable, an approximation of the minimal clinically important difference.38 Multivariable analysis was used to control for age, sex, race, educational attainment, and smoking history.

We also evaluated the impact of home oxygen use on the risk of cognitive impairment. Because oxygen therapy is prescribed to patients with more severe disease, confounding by indication will likely bias the unadjusted results in the direction of no effect. We used two approaches to control for confounding. First, we used standard multivariable logistic regression. Second, we used propensity scores to correct for confounding by indication. Propensity scores were developed from a multivariable logistic regression model to predict home oxygen use conditional on observed covariates. Variables included were age, sex, race, smoking history, BODE Score, FEV$_1$, baseline oxygen saturation ($\geq 88\%$), and desaturation during Six Minute Walk Test ($\geq 4\%$). Area under receiver operator characteristic curve for this model was excellent (0.92). Multivariable logistic regression analysis was then used to evaluate the impact of home oxygen use on the risk of cognitive impairment using inverse probability-weighted estimators derived from the propensity scores to control for confounding.39

The LOWESS (locally weighted regression scatter plot smoother) procedure was used to graphically depict the relationship between oxygen saturation and the logit (ie, log odds) of cognitive impairment. This method fitted a flexible smoothed curve that did not impose a linear relationship.40

Results
Baseline characteristics of subjects with and without COPD
Subjects with and without COPD were similar in age, sex, and race-ethnicity, which reflected matching ($P > 0.20$ in all cases) (Table 1). The prevalence of lifetime smoking was higher among those with COPD (87%) than in the referent group (48%) ($P < 0.0001$). Persons with COPD also had lower educational attainment than referents.

COPD and the risk of cognitive impairment
The prevalence of cognitive impairment was much higher among COPD subjects compared to the matched referent group without COPD (5.5% vs 2.0%, $P = 0.0051$). In multivariable analysis, COPD was associated with a greater risk of cognitive impairment function even after controlling for age, sex, race, smoking history, and educational attainment (OR 2.42, 95% CI 1.043–6.64) (Table 2).

Risk factors for cognitive impairment among subjects with COPD
Among patients with COPD, respiratory impairment, as measured by FEV$_1$, was not associated with cognitive impairment (Table 3). Low baseline oxygen saturation ($\geq 88\%$) was strongly related to cognitive impairment (adjusted OR 5.45; 95% CI 1.014–29.2). A small minority of subjects (n = 61) used prescribed supplemental oxygen. When oxygen use was added to the multivariable model, low oxygen saturation remained associated with a greater risk of cognitive impairment (OR 5.46; 95% CI 1.007–30). Figure 1 demonstrates that the risk of cognitive impairment increases with decreasing oxygen saturation, but that the relationship is non-linear.
The risk of cognitive impairment was not associated with COPD severity as defined by either the COPD severity score or BODE score (Table 3). Stroke and other cardiovascular disease were also not related to cognitive impairment (Table 4).

Home oxygen therapy and cognitive impairment in COPD

Home oxygen therapy was associated with a decreased risk of cognitive impairment among persons with COPD (Table 5). The unadjusted estimate, which was likely confounded by indication, did not exclude the ‘no effect’ level. In the most adjusted model, using inverse probability-weighted estimators derived from the propensity scores to control for confounding, home oxygen use was strongly associated with a decreased risk of cognitive impairment (OR 0.14; 95% CI 0.01–0.27).

Discussion

COPD is often considered a disease that solely affects the lungs; however, its extrapulmonary effects are profound and disabling. Our study indicates that COPD is strongly associated with cognitive impairment in a large cohort of patients with a broad range of COPD severity. Resting hypoxemia was the single most important risk factor for cognitive impairment; treatment with supplemental oxygen markedly decreased the risk. Lung function impairment, COPD severity, and cardiovascular disease did not appear to explain the development of cognitive impairment in COPD.

We used a rigorous and multifaceted approach to measuring COPD severity (lung function, COPD Severity Score, and BODE Index). Despite this approach, we found no impact of these indicators of disease severity on the risk of cognitive impairment. This differs from some previous work, but is similar to other studies that found no association between disease severity and cognitive impairment. Our results reveal a disconnect between global measures of COPD severity, which were not related to cognitive impairment, and decreased resting oxygenation, which was strongly associated with decreased cognitive function.

The specific role of cardiovascular comorbidities as a risk factor for cognitive impairment in COPD is difficult to ascertain as both conditions share risk factors (eg, smoking) and COPD patients may be predisposed to cardiovascular events. When cardiovascular comorbidities were evaluated as a risk factor for cognitive impairment, no association was found among the COPD cohort. The point estimate for cardiovascular disease was elevated, however, in the unadjusted analysis, so lack of statistical power may be one explanation.

Table 1 Baseline characteristics of FLOW cohort of COPD vs referent subjects

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>COPD (n = 1,202)</th>
<th>Referents (n = 302)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age in years, mean (SD)</td>
<td>58.2 (6.2)</td>
<td>58.5 (6.2)</td>
<td>0.50</td>
</tr>
<tr>
<td>Female, n (%)</td>
<td>691 (57.4%)</td>
<td>200 (66%)</td>
<td>0.23</td>
</tr>
<tr>
<td>Race/ethnicity, n (%)</td>
<td></td>
<td></td>
<td>0.96</td>
</tr>
<tr>
<td>White, non-Hispanic</td>
<td>810 (67%)</td>
<td>200 (66%)</td>
<td></td>
</tr>
<tr>
<td>African-American</td>
<td>206 (17%)</td>
<td>57 (19%)</td>
<td></td>
</tr>
<tr>
<td>Asian/Pacific Islander</td>
<td>35 (3%)</td>
<td>8 (3%)</td>
<td></td>
</tr>
<tr>
<td>Hispanic</td>
<td>111 (9%)</td>
<td>28 (9%)</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>40 (3%)</td>
<td>9 (3%)</td>
<td></td>
</tr>
<tr>
<td>Educational attainment, n (%)</td>
<td></td>
<td></td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>High school or less</td>
<td>352 (29%)</td>
<td>42 (14%)</td>
<td></td>
</tr>
<tr>
<td>Some college</td>
<td>524 (44%)</td>
<td>95 (31%)</td>
<td></td>
</tr>
<tr>
<td>College/graduate degree</td>
<td>326 (27%)</td>
<td>165 (55%)</td>
<td></td>
</tr>
<tr>
<td>Smoking status, n (%)</td>
<td></td>
<td></td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Never smoked</td>
<td>165 (13%)</td>
<td>158 (52%)</td>
<td></td>
</tr>
<tr>
<td>Current smoker</td>
<td>393 (33%)</td>
<td>12 (4%)</td>
<td></td>
</tr>
<tr>
<td>Ex-smoker</td>
<td>644 (54%)</td>
<td>132 (44%)</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: COPD, chronic obstructive pulmonary disease; FLOW, Function, Living, Outcomes and Work; SD, standard deviation.

Table 2 COPD and the risk of cognitive impairment

<table>
<thead>
<tr>
<th>Comparison</th>
<th>Unadjusted OR (95% CI)</th>
<th>Controlling for age, sex, race, educational attainment, and smoking history OR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Referent Group</td>
<td>1.0</td>
<td>1.0</td>
</tr>
<tr>
<td>COPD</td>
<td>2.86 (1.34–7.46)</td>
<td>2.42 (1.043–6.64)</td>
</tr>
</tbody>
</table>

Abbreviations: CI, confidence interval; OR, odds ratio.
COPD severity score: 1.08 (0.95–1.23)
Baseline oxygen saturation: 4.41 (0.92–21)
<88%: 1.13 (1.00–2.17)
BODE Score: 1.13 (1.00–1.27)
COPD Severity Score: 1.08 (0.94–1.23)

For this lack of effect. Controlling for covariates, such as smoking, reduced the effect estimate, so that any association between cardiovascular disease and cognitive impairment may be mediated by smoking and other factors.

Cognitive impairment may interfere with patients’ ability to adhere to their medication regimen, adjust their medications in response to respiratory symptoms, and perform other aspects of self-management. Given that many of the medications for COPD are self-activated, even mild degrees of cognitive impairment could have significant effects on disease management. More broadly, cognitive impairment may create difficulties with performing daily activities, especially those that involve memory or complex reasoning. It is likely that cognitive impairment has major effects on many aspects of patient functioning and health status.

The MMSE is a widely used measure of cognitive impairment but it is not sensitive for mild cognitive dysfunction. Consequently, our methods could have missed cases of mild cognitive impairment. It remains possible, therefore, that COPD severity could predict milder degrees of cognitive dysfunction. A future analysis of cognitive impairment using a detailed neuropsychologic battery of tests is required to evaluate milder cognitive impairment in COPD.

Our study is subject to several other limitations. Because our primary study focus was development of disability in COPD, we enrolled younger patients (45–65 years). Consequently, our study may underestimate the impact of COPD on cognitive impairment in older patients. Misclassification

### Table 3 Relationship between COPD severity and cognitive impairment

<table>
<thead>
<tr>
<th>Disease severity measure</th>
<th>Risk of cognitive impairment</th>
<th>Unadjusted OR (95% CI)</th>
<th>Multivariable OR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Forced expiratory volume in 1 second</td>
<td></td>
<td>0.97 (0.85–1.11)</td>
<td>0.93 (0.79–1.09)</td>
</tr>
<tr>
<td>Baseline oxygen saturation</td>
<td></td>
<td>4.41 (0.92–21)</td>
<td>5.45 (1.01–29.2)</td>
</tr>
<tr>
<td>&lt;88%</td>
<td></td>
<td>1.13 (1.01–1.27)</td>
<td>1.08 (0.95–1.23)</td>
</tr>
<tr>
<td>BODE Score</td>
<td></td>
<td>1.08 (0.94–1.23)</td>
<td>1.03 (0.90–1.17)</td>
</tr>
<tr>
<td>COPD Severity Score</td>
<td></td>
<td>1.08 (0.94–1.23)</td>
<td>1.03 (0.90–1.17)</td>
</tr>
</tbody>
</table>

*odds ratio per 0.5 standard deviation decrement.

<table>
<thead>
<tr>
<th>Cardiovascular disease</th>
<th>Risk of cognitive impairment</th>
<th>Unadjusted OR (95% CI)</th>
<th>Multivariable OR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stroke</td>
<td></td>
<td>0.81 (0.25–2.66)</td>
<td>0.78 (0.23–2.61)</td>
</tr>
<tr>
<td>Other cardiovascular disease</td>
<td></td>
<td>1.57 (0.92–2.69)</td>
<td>1.30 (0.74–2.31)</td>
</tr>
</tbody>
</table>

*Hypertension, coronary artery disease, or congestive heart failure.

### Table 4 Cardiovascular disease and the risk of cognitive impairment in COPD

### Table 5 Home oxygen use and the risk of cognitive impairment in COPD

<table>
<thead>
<tr>
<th>Statistical model</th>
<th>Risk of cognitive impairment OR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unadjusted</td>
<td>0.74 (0.26–1.71)</td>
</tr>
<tr>
<td>Multivariable model</td>
<td>0.40 (0.11–1.17)</td>
</tr>
<tr>
<td>Multivariable model(propensity score adjusted)</td>
<td>0.14 (0.07–0.27)</td>
</tr>
</tbody>
</table>

*Multivariable logistic regression analysis including home oxygen use plus age, sex, race, educational attainment, smoking history, baseline oxygen saturation, BODE Score, COPD Severity Score, FEV1, and height.

**Figure 1** Relationship between resting oxygen saturation and the risk of cognitive impairment. Oxygen saturation was measured using pulse oximetry. The LOWESS (locally weighted regression scatter plot smoother) procedure was used to graphically depict the relationship between oxygen saturation and the logit (ie, log odds) of cognitive impairment. This method fitted a flexible smoothed curve that did not impose a linear relationship.
of COPD could also have occurred. Our COPD definition required concomitant treatment with COPD medications to increase the specificity of our definition. In addition, all patients had a physician diagnosis of COPD and reported having the condition. The lifetime smoking prevalence was similar to that in other population-based epidemiologic studies of COPD, supporting the diagnosis of COPD rather than asthma.\textsuperscript{46-47} We also previously demonstrated the validity of our approach using medical record review.\textsuperscript{18} Nonetheless, we acknowledge this potential limitation.

Another limitation is the small proportion of subjects who were using home oxygen. Consequently, the confidence intervals around our estimates of the effectiveness of oxygen for preventing cognitive impairment are wide in some cases. As the FLOW cohort continues longitudinal follow-up, we will further evaluate the impact of oxygen therapy on cognitive function.

COPD is a multisystem disease with extrapulmonary sequelae. It is strongly associated with an increased risk of cognitive impairment, especially among hypoxemic patients. Clinicians should evaluate their COPD patients for cognitive impairment in order to identify those who may benefit from interventions such as medication assistance or supplemental oxygen therapy. Future research should use detailed neuropsychological testing to carefully evaluate multiple cognitive domains among subjects with a broad range of ages and disease severity.

Acknowledgment
Funded by: NHLBI/NIH R01HL077618 and K24 HL 097245.

Disclosure
The authors report no conflicts of interest in this work.

References